These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32207278)

  • 1. Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas.
    Kim J; Oh JH; Harlem H; Culler MD; Ku CR; Lee EJ
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):177-187. PubMed ID: 32207278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
    Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
    J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
    Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
    J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
    Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
    Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
    Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells.
    Tulipano G; Faggi L; Losa M; Mortini P; Spinello M; Sibilia V; Pagani F; Cocchi D; Giustina A
    Mol Cell Endocrinol; 2013 Jan; 365(2):197-206. PubMed ID: 23116772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
    Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
    J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas.
    Regazzo D; Avallone S; MacSweeney CP; Sergeev E; Howe D; Godwood A; Bennett KA; Brown AJH; Barnes M; Occhi G; Barbot M; Faggian D; Tropeano MP; Losa M; Lasio G; Scaroni C; Pecori Giraldi F
    Eur J Endocrinol; 2024 Jan; 190(1):K8-K16. PubMed ID: 38123488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial.
    de Boon WMI; van Esdonk MJ; Stuurman FE; Biermasz NR; Pons L; Paty I; Burggraaf J
    J Clin Endocrinol Metab; 2019 Mar; 104(3):883-891. PubMed ID: 30371791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Somatostatin Analogue Treatment Might Trigger Apoptosis and Autophagy in Tumor Tissues of Patients with Acromegaly: A Pilot Study.
    Dagistanli FK; Ozkaya HM; Kucukyoruk B; Biceroglu H; Metin D; Gazioglu N; Oz B; Kadioglu P; Ozturk M
    Exp Clin Endocrinol Diabetes; 2018 Mar; 126(3):168-175. PubMed ID: 27322826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
    Gruszka A; Culler MD; Melmed S
    Mol Cell Endocrinol; 2012 Oct; 362(1-2):104-9. PubMed ID: 22705877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
    Chahal HS; Trivellin G; Leontiou CA; Alband N; Fowkes RC; Tahir A; Igreja SC; Chapple JP; Jordan S; Lupp A; Schulz S; Ansorge O; Karavitaki N; Carlsen E; Wass JA; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2012 Aug; 97(8):E1411-20. PubMed ID: 22659247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
    Plöckinger U; Hoffmann U; Geese M; Lupp A; Buchfelder M; Flitsch J; Vajkoczy P; Jakob W; Saeger W; Schulz S; Dohrmann C
    Eur J Endocrinol; 2012 Feb; 166(2):223-34. PubMed ID: 22065857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of microRNAs in GH-secreting pituitary adenomas.
    Mao ZG; He DS; Zhou J; Yao B; Xiao WW; Chen CH; Zhu YH; Wang HJ
    Diagn Pathol; 2010 Dec; 5():79. PubMed ID: 21138567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.